AMG 714 is a fully human monoclonal antibody directed against interleukin-15 (“IL-15”) that is being developed under an agreement with Genmab A/S. IL-15 blockade has potential utility in a wide variety of inflammatory diseases including rheumatoid arthritis and psoriasis. Dosing of healthy volunteers with AMG 714 in a phase 1a clinical study has been completed. A multi-dose study of AMG 714 in psoriasis subjects is on-going.

This information is current as of February 27, 2008. Amgen’s product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen’s most recent Form 10-K and in Amgen’s periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.